Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

21 Jul 2012

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Cubist Pharmaceuticals, Inc. today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials.

13 Jul 2012

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012

Conference highlights utility of zebrafish for human disorder studies

Zebrafish, popular as aquarium fish, now have an important place in research labs as a model organism for studying human diseases.

8 Jul 2012

Signs that a child is seriously ill: Interview with Professor Middleton

There are several signs that indicate that a child is seriously ill. These can be spotted by parents, teachers and carers as well as by me or any other doctor or nurse.

4 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

Under-performance of small bowel biopsy a major reason behind underdiagnosis of celiac disease

Under-performance of small bowel biopsy during endoscopy may be a major reason that celiac disease remains underdiagnosed in the United States, according to a new study published online recently in Gastrointestinal Endoscopy. Investigators at the Celiac Disease Center at Columbia University Medical Center (CUMC) found that the rate of small bowel biopsy is low in this country.

30 Jun 2012

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Dr. Grace McCarthy, Chairman of the Board of The Foundation for Children with Intestinal and Liver Disorders (CH.I.L.D), today announced an important new partnership with the Canadian Institutes of Health Research (CIHR) to fund the creation of the Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of CIHR and the CH.I.L.D. Foundation.

30 Jun 2012

Rate of small bowel biopsy is low in the U.S.

30 Jun 2012

Gluten-free diet may not be a good choice for everyone

One of the latest trends in the food market and among celebrities is going gluten-free. Snack giant Frito-Lay has announced it will introduce new gluten-free labels and products, and Miley Cyrus has credited her recent weight loss to a gluten-free diet.

29 Jun 2012

Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Study explores role of L. reuteri against foodborne infection

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Cubist second quarter total net revenues increase 30% to $230.6M

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

EGF helps prevent inflammation-induced cancer

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

Conference highlights utility of zebrafish for human disorder studies

Signs that a child is seriously ill: Interview with Professor Middleton

USPTO issues notice of allowance to Avanir for NUEDEXTA

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Under-performance of small bowel biopsy a major reason behind underdiagnosis of celiac disease

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Rate of small bowel biopsy is low in the U.S.

Gluten-free diet may not be a good choice for everyone

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in